SR18662 is a potent inhibitor of Krüppel-like factor five (KLF5) with an IC50 of 4.4 nM and an analogue of ML264 (HY-19994) with improved inhibitory potency against colorectal cancer cells. SR18662 can be used for the study of colorectal cancer.
SR18662, an analog of ML264, exhibits enhanced inhibitory potency against colorectal cancer cells by effectively targeting Krüppel-like factor five (KLF5) with an IC50 value of 4.4 nM. It serves as a valuable tool for colorectal cancer research[1].
体内研究
SR18662 (intraperitoneal injection; 5-10 mg/kg; daily or twice daily; 5 days injection, days break, and 5 days) effectively suppresses tumor growth in a mouse xenograft model[1].
体外研究
SR18662 (0-10 μM; 24-72 hours) markedly attenuates the growth and proliferation of colorectal cancer (CRC) cells compared to treatment with the vehicle control or ML264 alone. Its enhanced efficacy in reducing the viability of various CRC cell lines is notable[1].
SR18662 (10 μM; 24-72 hours) induces a notable elevation in the quantity of apoptotic cells at both early and late stages in DLD-1 and HCT116 cells[1].
SR18662, at 1 μM concentration over 72 hours, decreases the expression of cyclins (specifically cyclins E, A2, and B1), as well as components of the MAPK pathway (p-Erk) and the WNT signaling pathway (p-GSK3 β) in cells[1].
搜索
